BRAF and melanoma: Here, we report, to our knowledge for the first time, that vemurafenib (VEM), an inhibitor of the B-Raf serine/threonine protein kinase, is enabled to modify the glycans structure influencing the metallomics profile in BRAF mutated melanoma cells.